Somatostatin replacement: A new strategy for treating diabetic retinopathy

Current Medicinal Chemistry

Volumn 20, Issue 26, 2013, Pages 3251-3257

  Hernández, Cristina ^a,b   Simó, Rafael ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Early Treatment of Diabetic Retinopathy ^*  (United States)

Author keywords

Diabetic retinopathy; Neurodegeneration; Somatostatin

Indexed keywords

OCTREOTIDE; SOMATOSTATIN; STREPTOZOCIN;

ARTICLE; DIABETIC RETINOPATHY; EXCITOTOXICITY; HUMAN; NERVE DEGENERATION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); STREPTOZOCIN DIABETES; SUBSTITUTION THERAPY; TOPICAL TREATMENT;

ANIMALS; DIABETIC RETINOPATHY; HUMANS; NEUROPROTECTIVE AGENTS; SOMATOSTATIN;

EID: 84883251306     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990024     Document Type: Article

References (78)

1. Simó, R.; Hernández, C.; European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Br. J. Ophthalmol., 2012, 96(10), 1285-1290.
2. Brazeau, P.; Vale, W.; Burgus, R.; Ling, N.; Butcher, M.; Rivier, J.; Guillemin, R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science, 1973, 179(4068), 77-79.
3. Krantic, S.; Goddard, I.; Saveanu, A.; Giannetti, N.; Fombonne, J.; Cardoso, A.; Jaquet, P.; Enjalbert, A. Novel modalities of somatostatin actions. Eur. J. Endocrinol., 2004, 151(6), 643-655.
4. Olias, G.; Viollet, C.; Kusserow, H.; Epelbaum, J.; Meyerhof, W. Regulation and function of somatostatin receptors. J. Neurochem., 2004, 89(5), 1057-1091.
5. Hoyer, D.; Bell, GI.; Berelowitz, M.; Epelbaum, J.; Feniuk, W.; Humphrey, P.P.; O'Carroll, A.M.; Patel, Y.C.; Schonbrunn, A.; Taylor, J.E. Classification and nomenclature of somatostatin receptors. Trends Pharmacol. Sci., 1995, 16(3), 86-88.
6. Buscail, L.; Esteve, J.P.; Saint-Laurent, N.; Bertrand, V.; Reisine, T.; O'Carroll, A.M.; Bell, G.I.; Schally, A.V.; Vaysse, N.; Susini, C. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc. Natl. Acad. Sci. U S A., 1995, 92(5), 1580-1584.
7. Yunker, W.K.; Smith, S.; Graves, C.; Davis, P.J.; Unniappan, D.; Rivier, J.E.; Peter, R.E.; Chang, J.P. Endogenous hypothalamic somatostatins differentially regulate growth hormone secretion from goldfish pituitary somatotropes in vitro. Endocrinology, 2003, 144(9), 4031-4041.
8. Ensinck, J.W.; Vogel, R.E.; Laschansky, E.C.; Koerker, D.J.; Prigeon, R.L.; Kahn, S.E.; D'Alessio, D.A. Endogenous somatostatin-28 modulates postprandial insulin secretion. Immunoneutralization studies in baboons. J. Clin. Invest., 1997, 100(9), 2295-2302.
9. Shimon, I.; Taylor, J.E.; Dong, J.Z.; Bitonte, R.A.; Kim, S.; Morgan, B.; Coy, D.H.; Culler, M.D.; Melmed, D. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroidstimulating hormone, and prolactin regulation. J. Clin. Invest., 1997, 99(4), 789-798.
10. Yamada, T.; Marshak, D.; Basinger, S.; Walsh, J.;, Morley, J.; Stell, W. Somatostatin-like immunoreactivity in the retina. Proc. Natl. Acad. Sci. U S A., 1980, 77(3), 1691-1695.
11. Yamada, T.; Basinger, S. Biosynthesis of somatostatin-like immunoreactivity by frog retinas in vitro. J. Neurochem., 1982, 39(6), 1539-1546.
12. Patel, Y.C.; Wheatley, T.; Ning, C. Multiple forms of immunoreactive somatostatin: comparison of distribution in neural and nonneural tissues and portal plasma of the rat. Endocrinology, 1981, 109(6), 1943-1949.
13. Ferreiro, D.M.; Head, V.A.; Edwards, R.H.; Sagar, S.M. Somatostatin mRNA and molecular forms during development of the rat retina. Brain Res. Dev. Brain. Res., 1990, 57(1), 15-19.
14. Sagar, S.M.; Rorstad, O.P.; Landis, D.M.; Arnold, M.A.; Martin, J.B. Somatostatin-like immunoreactive material in the rabbit retina. Brain Res., 1982, 244(1), 91-99.
15. Marshak, D.W.; Reeve, J.R.; Shively, J.E.; Hawke, D.; Takami, M.S.; Yamada, T. Structure of somatostatin isolated from bovine retina. J. Neurochem., 1983, 41(3), 601-606.
16. Spira, A.W.; Shimizu, Y.; Rorstad, O.P. Localization, chromatographic characterization, and development of somatostatin-like immunoreactivity in the guinea pig retina. J. Neurosci., 1984, 4(12), 3069-3079.
17. Hernández, C.; Carrasco, E.; Casamitjana, R.; Deulofeu, R.; García-Arumí, J.; Simó, R. Somatostatin Molecular Variants in the Vitreous Fluid: A Comparative Study between Diabetic Patients with Proliferative Diabetic Retinopathy and Non-Diabetic Control Subjects. Diabetes Care, 2005, 28(8), 1941-1947.
18. Simó, R.; Lecube, A.; Sararols, L.; García-Arumí, J.; Segura, R.M.; Casamitjana, R.; Hernández, C.; Deficit of somatostatin-like immunoreactivity in the vitreous fluid of diabetic patients: possible role in the development of proliferative diabetic retinopathy. Diabetes Care, 2002, 25(12), 2282-2286.
19. van Hagen, PM.; Baarsma, GS.; Mooy, CM.; Ercoskan, E.M.; ter Averst, E.; Hofland, L.J.; Lamberts, S.W.; Kuijpers, R.W. Somatostatin and somatostatin receptors in retinal diseases. Eur. J. Endocrinol., 2000, 143, S43-S51.
20. Feigenspan, A.; Bormann, J. Facilitation of GABAergic signalling in the retina by receptors stimulating adenylate cyclase. Proc. Natl. Acad. Sci. USA., 1994, 91(23), 10893-10897.
21. Carrasco, E.; Hernández, C.; Miralles, A.; Huguet, P.; Farrés, J.; Simó, R. Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care, 2007, 30(11), 2902-2908.
22. Lambooij, A.C.; Kuijpers, R.W.A.M.; van Lichtenauer-Kaligis, E.G.; Kliffen, M.; Baarsma, G.S.; van Hagen, P.M.; Mooy, C.M. Somatostatin receptor 2A expression in choroidal neovascularization secondary to age-related macular degeneration. Invest. Ophthalmol. Vis. Sci., 2000, 41(8), 2329-2335.
23. Klisovic, D.D.; O'Dorisio, M.S.; Katz, S.E.; Sall, J.W.; Balster, D.; O'Dorisio, T.M.; Craig, E.; Lubow, M. Somatostatin receptor gene expression in human ocular tissues: RT-PCR and immunohistochemical study. Invest. Ophthalmol. Vis. Sci., 2001, 42(10), 2193-2201.
24. Cervia, D.; Casini, G.; Bagnoli, P. Physiology and pathology of somatostatin in the mammalian retina: a current view. Mol. Cell. Endocrinol., 2008, 286(1-2), 112-122.
25. Patel, Y.C.; Srikant, C.B. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology, 1994, 135(6), 2814-1817.
26. Patel, Y.C.; Greenwood, M.; Panetta, R.; Hukovic, N.; Grigorakis, S.; Robertson, L.A.; Srikant, C.B. Molecular biology of somatostatin receptor subtypes. Metabolism, 1996, 45(8), 31-38.
27. Pulido, J.E.; Pulido, J.S.; Erie, J.C.; Arroyo, J.; Bertram, K.; Lu, M.J.; Shippy, S.A. A role for excitatory amino acids in diabetic eye disease. Exp. Diabetes Res., 2007, 2007: 36150.
28. Ng, Y.K.; Zeng, X.X.; Ling E.A. Expression of glutamate receptors and calcium-binding proteins in the retina of streptozotocininduced diabetic rats. Brain Res., 2004, 1018(1), 66-72.
29. Santiago, A.R.; Gaspar, J.M.; Baptista, F.I.; Cristóvão, A.J.; Santos, P.F.; Kamphuis, W.; Ambrósio, A.F. Diabetes changes the levels of ionotropic glutamate receptors in the rat retina. Mol. Vis., 2009, 15, 1620-1630.
30. Bigiani, A.; Petrucci, C.; Ghiaroni, V.; Dal Monte, M.; Cozzi, A.; Kreienkamp, H J.;Richter D, Bagnoli, P. Functional correlates of somatostatin receptor 2 overexpression in the retina of mice with genetic deletion of somatostatin receptor 1. Brain Res., 2004, 1025(1-2), 177-185.
31. Catalani, E.; Cervia, D.; Martini, D.; Bagnoli, P.; Simonetti, E.; Timperio, A.M.; Casini, G. Changes in neuronal response to ischemia in retinas with genetic alterations of somatostatin receptor expression. Eur. J. Neurosci., 2007, 25(5), 1447-1459.
32. Akopian, A.; Johnson, J.; Gabriel, R.; Brecha, N.; Witkovsky, P. Somatostatin modulates voltage-gated K(+) and Ca(2+) currents in rod and cone photoreceptors of the salamander retina. J. Neurosci., 2000, 20(3), 929-936.
33. Dal Monte, M.; Petrucci, C.; Cozzi, A.; Allen, J.P.; Bagnoli, P. Somatostatin inhibits potassium-evoked glutamate release by activation of the sst(2) somatostatin receptor in the mouse retina. Naunyn Schmiedebergs Arch. Pharmacol., 2003, 367(2), 188-192.
34. Kouvidi, E.; Papadopoulou-Daifoti, Z.; Thermos, K. Somatostatin modulates dopamine release in rat retina. Neurosci. Lett., 2006, 391(3), 82-86.
35. Mastrodimou, N.; Vasilaki, A.; Papadioti, A.; Low, MJ.; Hoyer, D.; Thermos, K. Somatostatin receptors in wildtype and somatostatin deficient mice and their involvement in nitric oxide physiology in the retina. Neuropeptides, 2006, 40(5), 365-373.
36. Bloomfield, S.A.; Völgyi, B. The diverse functional roles and regulation of neuronal gap junctions in the retina. Nat. Rev. Neurosci., 2009, 10(7), 495-506.
37. Mastrodimou, N.; Kiagiadaki, F.; Hodjarova, M.; Karagianni, E.; Thermos, K. Somatostatin receptors (sst2) regulate cGMP production in rat retina. Regul. Pept., 2006, 133(1-3), 41-46.
38. Kiagiadaki, F.; Thermos, K. Effect of intravitreal administration of somatostatin and sst2 analogs on AMPA-induced neurotoxicity in rat retina. Invest. Ophthalmol. Vis. Sci., 2008, 49(7), 3080-3089.
39. Kiagiadaki, F.; Savvaki, M.; Thermos, K. Activation of somatostatin receptor (sst 5) protects the rat retina from AMPA-induced neurotoxicity. Neuropharmacology, 2010, 58(1), 297-303.
40. Kokona, D.; Mastrodimou, N.; Pediaditakis, I.; Charalampopoulos, I.; Schmid, HA.; Thermos, K. Pasireotide (SOM230) protects the retina in animal models of ischemia induced retinopathies. Exp. Eye. Res., 2012, 103, 90-98.
41. Saito, T.; Iwata, N.; Tsubuki,S.; Takaki, Y.; Takano, J.; Huang, S.M.; Suemoto, T.; Higuchi, M.; Saido, T.C. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat. Med., 2005, 11(4), 434-439.
42. Yasojima, K.; Akiyama, H.; McGeer, E.G.; McGeer ,P.L. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci. Lett., 2001, 297(2), 97-100.
43. Schmitt, F.; Ryan, M.; Cooper, G. A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer's disease. Expert Opin. Drug. Metab. Toxicol., 2007, 3(1), 135-141.
44. Smith, L.E.; Kopchick, J.J.; Chen, W.; Knapp, J.; Kinose, F.; Daley, D.; Foley, E.; Smith, R.G.; Schaeffer, J.M. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science, 1997, 276(5319), 1706-1709.
45. Davis, M.I.; Wilson, S.H.; Grant, M.B. The therapeutic problem of proliferative diabetic retinopathy: targeting somatostatin receptors. Horm. Metab. Res., 2001, 33(5), 295-299.
46. Wilson, S.H.; Davis, M.I.; Caballero, S.; Grant, M.B. Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogues: implications for diabetic retinopathy. Growth Horm. IGF Res., 2001, 11 (Suppl A):S53-S59.
47. Baldysiak-Figiel, A.; Lang, G.K.; Kampmeier, J.; Lang, G.E. Octreotide prevents growth factor-induced proliferation of bovine retinal endothelial cells under hypoxia. J. Endocrinol., 2004, 180(3)417-424.
48. Mei, S.; Cammalleri, M.; Azara, D.; Casini, G.; Bagnoli, P.; Dal Monte, M. Mechanisms underlying somatostatin receptor 2 downregulation of vascular endothelial growth factor expression in response to hypoxia in mouse retinal explants. J. Pathol., 2012, 226(3), 519-533.
49. Dal Monte, M.; Cammalleri, M.; Martini, D.; Casini, G.; Bagnoli, P. Antiangiogenic role of somatostatin receptor 2 in a model of hypoxia-induced neovascularization in the retina: results from transgenic mice. Invest. Ophthalmol .Vis. Sci., 2007, 48(8), 3480-3489.
50. Higgins, R.D.; Yan, Y.; Schrier, B.K. Somatostatin analogs inhibit neonatal retinal neovascularization. Exp. Eye. Res., 2002, 74(5), 553-559.
51. Dal Monte, M.; Ristori, C.; Videau, C.; Loudes, C.; Martini, D.; Casini, G.; Epelbaum, J.; Bagnoli, P. Expression, localization, and functional coupling of the somatostatin receptor subtype 2 in a mouse model of oxygen-induced retinopathy. Invest. Ophthalmol. Vis. Sci., 2010, 51(4), 1848-1856.
52. Averbukh, E.; Halpert, M.; Yanko, R.; Yanko, L.; Peèr, J.; Levinger, S.; Flyvbjerg, A.; Raz, I. Octreotide, a somatostatin analogue, fails to inhibit hypoxia-induced retinal neovascularization in the neonatal rat. Int. J. Exp. Diabetes Res., 2000, 1(1), 39-47.
53. Palii, S.S.; Afzal, A.; Shaw, L.C.; Pan, H.; Caballero, S.; Miller, R.C.; Jurczyk, S.; Reubi, J.C.; Tan, Y.; Hochhaus, G.; Edelhauser, H.; Geroski, D.; Shapiro, G.; Grant, M.B. Nonpeptide somatostatin receptor agonists specifically target ocular neovascularization via the somatostatin type 2 receptor. Invest. Ophthalmol. Vis. Sci., 2008, 49(11), 5094-5102.
54. Hesse, U.; Ysebaert, D.; de Hemptinne, B. Role of somatostatin-14 and its analogues in the management of gastrointestinal fistulae: clinical data. Gut, 2001, 49 (Suppl 4):iv11-21.
55. Ray, C.; Carney, S.; Morgan, T.; Gillies, A. Somatostatin as a modulator of distal nephron water permeability. Clin. Sci. (Lond), 1993, 84(4), 455-460.
56. Corraliza, L.; García-Ramírez, M.; Villarroel, M.; Ciudin, A.; Hernández, C.; Simó, R. Somatostatin 28 (SST-28) prevents the breakdown of human retinal pigment epithelial cells induced by the diabetic milieu. Diabetologia, 2010, 53, [Suppl 1]:A1191.
57. Barber, A.J.; Lieth, E.; Khin, S.A.; Antonetti, D.A.; Buchanan, A.G.; Gardner, T.W. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J. Clin. Invest., 1998, 102, 783-791.
58. Kern, T.S.; Barber, A.J. Retinal ganglion cells in diabetes. J. Physiol., 2008, 586, 4401-4408.
59. Simó, R.; Carrasco, E.; Fonollosa, A.; García-Arumí, J.; Casamitjana, R. Hernández, C. Deficit of somatostatin in the vitreous fluid of patients with diabetic macular edema. Diabetes Care, 2007, 30(3), 725-727.
60. Hernández, C.; Simó, R. Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice. Expert. Opin. Investig. Drugs., 2007, 6(8), 1209-1226.
61. Hernández, C.; García-Ramírez, M.; Corraliza, L.; Fernández-Carneado, J.; Farrera-Sinfreu, J.; Ponsati, B.; González-Rodríguez, A.; Martínez-Valverde, A.; Simó, R. Topical administration of somatostatin prevents retinal neurodegeneration in experimental diabetes. Diabetes, 2013, Mar 8. [Epub ahead of print].
62. Holopigian, K.; Seiple, W.; Lorenzo, M.; Carr, R. A comparison of photopic and scotopic electroretinographic changes in early diabetic retinopathy. Invest. Ophthalmol. Vis. Sci., 1992, 33(10), 2773-2780.
63. Lieth, E.; Barber, A.J.; Xu, B.; Dice, C.; Ratz, M.J.; Tanase, D.; Strother, J.M. Glial reactivity and impaired glutamate metabolism in short-Term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes, 1988, 47(5), 815-820.
64. Lieth, E.; LaNoue, K.F.; Antonetti, D.A.; Ratz, M. Diabetes reduces glutamate oxidation and glutamine synthesis in the retina. The Penn State Retina Research Group. Exp. Eye, 2000, 70(6), 723-730.
65. Kowluru, R.A.; Engerman, R.L.; Case, G.L.; Kern T.S. Retinal glutamate in diabetes and effect of antioxidants. Neurochem. Int., 2001, 38(5), 385-390.
66. Ambati, J.; Chalam, K.V.; Chawla, D.K.; D'Angio, C.T.; Guillet, E.G.; Rose, S.J. Vanderlinde, R.E.; Ambati, B.K.; Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch. Ophthalmol., 1997, 115(5), 1161-1166.
67. Rauen, T.; Rothstein, J.D.; Wässle, H. Differential expression of three glutamate transporter subtypes in the rat retina. Cell Tissue Res., 1996, 286(3), 325-336.
68. Grant, M.B.; Mames, R.N.; Fitzgerald, C.; Hazariwala, K.M.; Cooper-DeHoff, R.; Caballero, S.; Estes, K.S. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care, 2000, 23(4), 504-509.
69. Boehm, B.O.; Lang, G.K.; Jehle, P.M.; Feldman, B.; Lang, G.E. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm. Metab. Res., 2001, 33(5), 300-306.
70. Hernaez-Ortega, M.C.; Soto-Pedre, E.; Martin, J.J. Sandostatin LAR for cystoid diabetic macular edema: a 1-year experience. Diabetes Res. Clin. Pract., 2004, 64(1), 71-72.
71. Hernaez-Ortega, M.C.; Soto-Pedre, E.; Piniés, J.A. Lanreotide Autogel for persistent diabetic macular edema. Diabetes Res. Clin. Pract., 2008, 80(3), e8-e10.
72. Janssen, J.; Lamberts, S. Circulating IGF-1 and its protective role in the pathogenesis of diabetic angiopathy. Clin. Endocrinol., 2000, 52(1), 1-9.
73. Wang, Q.; Dills, D.; Klein, R.; Klein, B.; Moss, S. Does insulinlike growth factor 1 predict incidence and progression of diabetic retinopathy? Diabetes, 1995, 44(2), 161-164.
74. Palii, S.S.; Caballero, S Jr.; Shapiro, G.; Grant M.B. Medical treatment of diabetic retinopathy with somatostatin analogues. Expert Opin. Investig. Drugs, 2007, 16(1), 73-82.
75. Gerhardinger, C.; McClure, K D.; Romeo, G.; Podestà, F.; Lorenzi, M. IGF-I mRNA and signaling in the diabetic retina. Diabetes, 2000, 50(1), 175-183.
76. Simó, R.; Hernández, C.; Segura, RM.; García- Arumí, J.; Sararols, L.; Burgos, R.; Cantón, A.; Mesa, J. Free insulin-like growth factor 1 in the vitreous fluid of diabetic patients with proliferative diabetic retinopathy: a case-control study. Clin. Sci. (Lond), 2003, 104(3), 223-230.
77. Aiello, L.P. Targeting intraocular neovascularization and edemaone drop at a time. N. Engl. J. Med., 2008, 359(9), 967-969.
78. Cheung, N.; Mitchell, P.; Wong, T.Y. Diabetic retinopathy. Lancet, 2010, 376(9735), 124-136.